Previous close | 1.6900 |
Open | 1.6500 |
Bid | 1.5700 x 100 |
Ask | 1.6800 x 100 |
Day's range | 1.6000 - 1.7100 |
52-week range | 0.2530 - 3.4000 |
Volume | |
Avg. volume | 844,870 |
Market cap | 12.27M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.6300 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on April 23, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2). Mark White, CEO of Nexalin, stated, “We remain committed to our mission of revolutionizing the treatment of mental health and neurological condi
Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic modelHOUSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided the following letter to shareholders from the Company’s CEO, Mark White, including updates regarding the growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as, prog
The new Gen-3 HALO™ Clarity 15 milliamp (mA) The new Gen-3 HALO™ Clarity 15 milliamp (mA) The new Gen-3 HALO™ Clarity 15 milliamp (mA) HOUSTON, TX, April 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced it has completed the first full production test run and successfully performed usability, feasibility design verification, and electrical safety testing for its new Gen-3 HALO™ Clarity 15 milliamp (mA) neurostimulation device